SCHEMBL4568321

SCHEMBL4568321

CCOC(=O)c1cccc(C(O)c2c(-c3ccccc3)[nH]c3cc(C)c(C)cc23)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
MAPK10 P53779 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.43
GABRA2 P47869 5/20 0.43
GABRB2 P47870 4/20 0.43
GABRA1 P14867 3/20 0.43
GABRG2 P18507 3/20 0.43
GABRB3 P28472 3/20 0.43
GABRA5 P31644 3/20 0.43
GABRA3 P34903 3/20 0.43
GABRP O00591 2/20 0.43
GABRD O14764 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568311 0.87 NPC1 (0.40) MAPTKDM4EALDH1A1LMNAMEN1
SCHEMBL4568338 0.86 MAPT (0.39) MAPTKDM4EALDH1A1LMNAMEN1
SCHEMBL15998657 0.84 KDM4E (0.39) MAPTKDM4EALDH1A1LMNAMEN1
SCHEMBL3714696 0.83 MAPT (0.43) MAPTKDM4EALDH1A1LMNAMEN1
SCHEMBL4568323 0.80 NR4A2 (0.41) MAPTKDM4EALDH1A1LMNAHPGD
SCHEMBL4568313 0.80 PDE3B (0.46) MAPTKDM4EALDH1A1LMNAMEN1
SCHEMBL4568334 0.79 MAPT (0.39) MAPTKDM4EALDH1A1LMNAMEN1
SCHEMBL15998654 0.79 KDM4E (0.43) KDM4ELMNA
SCHEMBL3701212 0.79 MMP2 (0.43) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4568517 0.78 KDM4E (0.46) MAPTKDM4EALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MAPT 3199/4885KDM4E 3521/4885ALDH1A1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.